Researchers in Switzerland reported Monday that doctors can gauge how well their HIV-positive patients are responding to anti-HIV drugs--or if they're taking their medications as prescribed--by analyzing a sample of each patient's hair, Reuters Health reports. According to the researchers' study, published in the October issue of the Annals of Internal Medicine, hair samples contain traces of anti-HIV drugs that can be measured and linked with treatment efficacy. Hair samples that showed low levels of Crixivan, which was the drug studied by the researchers, were linked with patients who were not taking their medication consistently or who had trouble absorbing it into their bodies, both of which can lead to treatment failure and drug-resistant virus. High levels of the drug detected in the hair samples were linked with treatment success as measured by blood-based viral loads. The higher the amount the drug detected in the hair, the more likely the patient was to have undetectable blood-based viral loads, according to the study. "Given the importance of long-term adherence to antiretroviral therapies for optimal outcome, hair analysis represents a significant, convenient, and affordable advance in assessing exposure to antiretroviral therapies over extended periods," wrote Monica Gandhi and Ruth Greenblatt of the University of California, San Francisco, in an editorial accompanying the study in the journal.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














